+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07215884

Evaluating Aripiprazole and Sensorimotor Speech Processing in Adults Who Stutter

Led by University of California, San Francisco · Updated on 2026-08-19

25

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of aripiprazole on adults who stutter, a condition that affects speech fluency and impacts millions. The study aims to understand how dopamine regulation and auditory feedback changes influence sensorimotor speech pathways. This research could support future combined treatments involving dopamine regulators and behavioral approaches. Participants will receive either a single 10 mg oral dose of aripiprazole or a placebo in a randomized, crossover design with triple masking. The study investigates how these treatments affect speech fluency and neural responses related to auditory feedback and sensorimotor function. During the study, participants undergo assessments 3 to 4 hours after dosing, including measurements of pre-speech auditory modulation, speaking induced suppression, centering, and feedback alterations. The study involves healthy adult participants aged 18 to 65 years who are native American English speakers and have confirmed stuttering since childhood.

CONDITIONS

Brief Title

Dopamine and Sensorimotor Function in Stuttering

Research Team

N

Natalie Brunwin, MS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here